Oakmont Advisory Group’s Bristol-Myers Squibb BMY Stock Holding History

Oakmont Advisory Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.26K	Buy	+39	New	+$2.24K	﹤0.01%	409

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Oakmont Advisory Group's BMY Position: Q2 2026 in Review

Oakmont Advisory Group opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 39 shares worth $2.26K. The stake represents ﹤0.01% of the portfolio and ranks #409 among its holdings.

2,502 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Oakmont Advisory Group held 39 shares of Bristol-Myers Squibb worth $2.26K as of Q2 2026.
Bristol-Myers Squibb was a new Oakmont Advisory Group position in Q2 2026.
Bristol-Myers Squibb made up ﹤0.01% of Oakmont Advisory Group's portfolio in Q2 2026, its #409 holding.
2,502 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Oakmont Advisory Group's 13F filing for Q2 2026, filed 3 Aug 2026.